Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1and TSC2 Inactivating Alterations

Home Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1and TSC2 Inactivating Alterations

Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1and TSC2 Inactivating Alterations

/ Publications

Share the Post

About the Author

webmaster

Related Posts

New Drug Trial Gives Hope for Treatment-Resistant Epilepsy
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
Read More
Neil Desai, PhD
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)
Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With nab-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial
nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts